Why minocycline can cause systemic lupus - A hypothesis and suggestions for therapeutic interventions based on it

Medical Hypotheses

Volumn 63, Issue 1, 2004, Pages 31-34

  Van Steensel, M A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; MINOCYCLINE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; BRAIN INJURY; CELL DAMAGE; CELL PROTECTION; CELL TYPE; CEREBROVASCULAR ACCIDENT; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; KERATINOCYTE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 3042760947     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.12.040     Document Type: Article

References (41)

1. Rossman R.E. Minocycline treatment of tetracycline-resistant and tetracycline-responsive acne vulgaris. Cutis. 27:1981;196-197. 201, 207
2. Tubach F., Kaplan G., Berenbaum F. Highly positive dsDNA antibodies in minocycline-induced lupus. Clin. Exp. Rheumatol. 17:1999;124-125
3. Schlienger R.G., Bircher A.J., Meier C.R. Minocycline-induced lupus. A systematic review. Dermatology. 200:2000;223-231
4. Dunphy J., Oliver M., Rands A.L., Lovell C.R., McHugh N.J. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br. J. Dermatol. 142:2000;461-467
5. Adhami E. A predictive equation for drug-induced lupus. Med. Hypotheses. 61:2003;473-476
6. Knowles S.R., Shapiro L.E., Shear N.H. Reactive metabolites and adverse drug reactions: clinical considerations. Clin. Rev. Allergy Immunol. 24:2003;229-238
7. Schuler M., Green D.R. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans. 29:2001;684-688
8. Henry H., Thomas A., Shen Y., White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene. 21:2002;748-760
9. Drenou B., Blancheteau V., Burgess D.H., Fauchet R., Charron D.J., Mooney N.A. A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J. Immunol. 163:1999;4115-4124
10. Wells J.E., Hurlbert R.J., Fehlings M.G., Yong V.W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain. 126:2003;1628-1637
11. Thomas M., Le W.D., Jankovic J. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin. Neuropharmacol. 26:2003;18-23
12. Arvin K.L., Han B.H., Du Y., Lin S.Z., Paul S.M., Holtzman D.M. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. 52:2002;54-61
13. van Den Bosch L., Tilkin P., Lemmens G., Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 13:2002;1067-1070
14. Popovic N., Schubart A., Goetz B.D., Zhang S.C., Linington C., Duncan I.D. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51:2002;215-223
15. Du Y., Ma Z., Lin S., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;14669-14674
16. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA. 95:1998;15769-15774
17. Chen M., Ona V.O., Li M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:2000;797-801
18. Lin S., Zhang Y., Dodel R., Farlow M.R., Paul S.M., Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci. Lett. 315:2001;61-64
19. Wu D.C., Jackson-Lewis V., Vila M., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22:2002;1763-1771
20. Cleaver J.E., Crowley E. UV damage, DNA repair and skin carcinogenesis. Front. Biosci. 7:2002;d1024-d1043
21. White S., Rosen A. Apoptosis in systemic lupus erythematosus. Curr. Opin. Rheumatol. 15:2003;557-562
22. Cohen P.L., Caricchio R., Abraham V., et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196:2002;135-140
23. Bijl M., Limburg P.C., Kallenberg C.G. New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth. J. Med. 59:2001;66-75
24. Yasutomo K., Horiuchi T., Kagami S., et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28:2001;313-314
25. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25:2000;177-181
26. Dieker J.W., van der Vlag J., Berden J.H. Triggers for anti-chromatin autoantibody production in SLE. Lupus. 11:2002;856-864
27. Walport M.J. Lupus, DNase and defective disposal of cellular debris. Nat. Genet. 25:2000;135-136
28. Botto M., Dell'Agnola C., Bygrave A.E., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:1998;56-59
29. Botto M., Walport M.J. C1q, autoimmunity and apoptosis. Immunobiology. 205:2002;395-406
30. Trendelenburg M., Schifferli J.A. Apoptosis and C1q: possible explanations for the pathogenesis of systemic lupus erythematosus. Z. Rheumatol. 59:2000;172-175
31. Jackson C.E., Puck J.M. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr. Opin. Pediatr. 11:1999;521-527
32. Eyanson S., Greist M.C., Brandt K.D., Skinner B. Systemic lupus erythematosus: association with psoralen-ultraviolet. A treatment of psoriasis. Arch. Dermatol. 115:1979;54-56
33. Wang X., Zhu S., Drozda M., et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA. 100:2003;10483-10487
34. Sordet O., Rebe C., Plenchette S., et al. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood. 100:2002;4446-44453
35. Deng Y., Lin Y., Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16:2002;33-45
36. Lavie G., Kaplinsky C., Toren A., et al. A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: possible relevance to photodynamic therapy. Br. J. Cancer. 79:1999;423-432
37. Kettaneh A., Fain O., Ziol M., et al. Minocycline-induced systemic adverse reaction with liver and bone marrow granulomas and Sezary-like cells. Am. J. Med. 108:2000;353-354
38. Dewair M.A., Matthaei H. Tissue specificity of nonhistone proteins from human chromatin. Mol. Gen. Genet. 146:1976;309-312
39. Knudson C.M., Tung K.S., Tourtellotte W.G., Brown G.A., Korsmeyer S.J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 270:1995;96-99
40. Pedersen R.S., Bistrup C. Etoposide: more effective and less bone-marrow toxic than standard immunosuppressive therapy in systemic vasculitis? Nephrol. Dial. Transplant. 11:1996;1121-1123
41. Takahashi T., Tanaka M., Brannan C.I., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976